- Home
- PUBM vs LXRX Comparison
PUBM vs LXRX Comparison
Compare PUBM & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUBM
- LXRX
- Stock Information
- Founded
- PUBM 2006
- LXRX 1995
- Country
- PUBM United States
- LXRX United States
- Employees
- PUBM N/A
- LXRX N/A
- Industry
- PUBM Computer Software: Prepackaged Software
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- PUBM Technology
- LXRX Health Care
- Exchange
- PUBM Nasdaq
- LXRX Nasdaq
- Market Cap
- PUBM 382.7M
- LXRX 428.8M
- IPO Year
- PUBM 2020
- LXRX 2000
- Fundamental
- Price
- PUBM $8.22
- LXRX $1.15
- Analyst Decision
- PUBM Buy
- LXRX Buy
- Analyst Count
- PUBM 11
- LXRX 5
- Target Price
- PUBM $18.05
- LXRX $3.23
- AVG Volume (30 Days)
- PUBM 626.1K
- LXRX 1.7M
- Earning Date
- PUBM 11-11-2025
- LXRX 11-11-2025
- Dividend Yield
- PUBM N/A
- LXRX N/A
- EPS Growth
- PUBM N/A
- LXRX N/A
- EPS
- PUBM N/A
- LXRX N/A
- Revenue
- PUBM $292,208,000.00
- LXRX $58,432,000.00
- Revenue This Year
- PUBM N/A
- LXRX N/A
- Revenue Next Year
- PUBM $1.70
- LXRX N/A
- P/E Ratio
- PUBM N/A
- LXRX N/A
- Revenue Growth
- PUBM 3.53
- LXRX 1504.83
- 52 Week Low
- PUBM $7.01
- LXRX $0.28
- 52 Week High
- PUBM $17.74
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- PUBM 38.83
- LXRX 54.28
- Support Level
- PUBM $8.04
- LXRX $1.03
- Resistance Level
- PUBM $8.54
- LXRX $1.15
- Average True Range (ATR)
- PUBM 0.31
- LXRX 0.06
- MACD
- PUBM 0.11
- LXRX -0.00
- Stochastic Oscillator
- PUBM 18.97
- LXRX 70.59
About PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.